Nebenwirkungen · Neupro
Neupro 1 mg/24 h transdermal patch Neupro 3 mg/24 h transdermal patch · Abschnitt 4.8 · PDF-Seite 6–7
HOS-114664 · Präparat HOS-094135
6 In trials where the application sites were rotated as reflected in the instructions provided in the SmPC and package leaflet, 34.2% of 748 patients using Neupro, experienced application site reactions. The majority of application site reactions were mild or moderate in intensity, limited to the application areas and resulted in discontinuation of Neupro in 7.2% of subjects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T15:00:00Z · SHA-256 8c1c13f4377b291e92778d0cf7bf84640db85e338315a5f9bf30e0c0a33c9a3d · Passage 78586bee78f537af2a2dfdea6bdbf6d8ed0d59159c375019d049602e4bb923d3 · Zeichen 681–1060 im Abschnitt